National Institutes of Health Grants Exclusive Evaluation Option License to Thirsty Brook Bioscience for Modified T-cell Treatment of Multiple Myeloma

Summary

The National Institutes of Health is issuing a notice of intent to grant an exclusive evaluation option license to Thirsty Brook Bioscience, Inc. for the development of modified T-cells for treating multiple myeloma, as outlined in US Patent Applications 61/622,6008 and subject to US patent rights held by the US government.